Adjusted EBITDA (as defined below) loss in the first half of 2022 was Euro 136.0 mn compared to an adjusted EBITDA loss of Euro 80.1 mn in the first half of 2021. In the first half of 2022, Valneva generated a net loss of Euro 171.5 mn compared to a net loss of Euro 86.4 mn in the first half of 2021. Thomas Lingelbach, Valneva's Chief Executive Officer, commented, "Valneva continued to achieve significant R&D milestones in the first half of the year. Our updated Lyme disease collaboration agreement with Pfizer included a substantial equity investment which we see as a strong sign of confidence and recognition of our vaccine expertise, and the recent Phase 3 initiation brings us a step closer to a potential vaccine solution against Lyme disease. Our chikungunya vaccine program successfully met all Phase 3 clinical endpoints, readying us for BLA submission.